DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Jaypirca - 2 LLY.N - 1 Christy Santhosh - 1 Arun Koyyur - 1 Colin Bristow - 1 Bristow - 1 Lilly - 1
Top related locs:
Bengaluru U.S
Top related orgs:
U.S . Food - 1 Drug Administration - 1 FDA - 1 National Institutes of Health - 1 CLL - 1 Thomson - 1 UBS - 1 Food - 1

Search resuls for: "Jaypirca"


4 mentions found


☆ US FDA gives second approval to Eli Lilly's drug for type of blood cancer
  + stars: | 2023-12-01 | by ( ) www.reuters.com   time to read: +1 min
Dec 1 (Reuters) - Eli Lilly (LLY.N) said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer. The company said the health regulator gave the new approval to the drug for the treatment of chronic lymphocytic leukemia (CLL), a type of cancer in which the bone marrow makes too many of certain white blood cells. Jaypirca was first given accelerated approval by the FDA on Jan. 27 for the treatment of mantle cell lymphoma (MCL), a rare type of blood cancer that starts in white blood cells and spreads to other parts of the body. MCL is a more aggressive form of cancer compared to CLL, according to the National Institutes of Health. The drug aims to treat adults with CLL after at least two lines of therapy.
Persons: Eli Lilly, LLY.N, Jaypirca, Christy Santhosh, Arun Koyyur Organizations: U.S . Food, Drug Administration, FDA, National Institutes of Health, CLL, Thomson Locations: Bengaluru
☆ UBS says this stock is the 'best story' among U.S. large caps, sees more than 15% upside ahead
  + stars: | 2023-08-14 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +3 min
Calling it the "best fundamental story" among U.S. large caps, UBS analyst Colin Bristow on Friday lifted his price target to $612 from $526. The stock has already gained 47% year to date, mostly on the back of lofty expectations for weight loss drug sales. Bristow also expects data for its Crohn's disease treatment by year-end, as well as readouts on Verzenio for prostate cancer. Then by 2024, Lilly is expected to submit data for a cell therapy for type 1 diabetes. And there's potential for even more upside if the drug adds other indications such as renal treatment, he said.
Persons: Eli Lilly, Colin Bristow, Bristow, Lilly, Jaypirca, Novo's, — CNBC's Michael Bloom Organizations: UBS, Food, Drug, European Union, Novo Locations: U.S
☆ Eli Lilly to invest additional $1.6 bln in 2 new plants
  + stars: | 2023-04-17 | by ( ) www.reuters.com   time to read: +1 min
April 17 (Reuters) - Eli Lilly and Co (LLY.N) said on Monday it will invest an additional $1.6 billion at its two new manufacturing sites in Indiana, United States to support the manufacturing of its recently approved cancer drug, Jaypirca, among others. The company's total investment commitment in the facilities now stands at $3.7 billion, Eli Lilly said. The company in January announced plans to invest an additional $450 million to expand capacity of a plant in North Carolina and meet the strong demand for its blockbuster diabetes drug Trulicity and recently launched Mounjaro. Its commitments for expansion of the North Carolina site are $1.7 billion. Reporting by Leroy Leo in Bengaluru; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.
☆ FDA approves Eli Lilly's drug for rare blood cancer
  + stars: | 2023-01-27 | by ( ) www.reuters.com   time to read: +1 min
Jan 27 (Reuters) - Eli Lilly and Co said on Friday the U.S. health regulator approved its drug for the treatment of a rare form of blood cancer. The wholesale cost of the treatment, Jaypirca, will be $21,000 per 30 days for the 200 mg dose, the U.S. drugmaker told Reuters. The Food and Drug Administration's accelerated approval for Jaypirca marks the first of the five treatments the U.S. drugmaker hopes to launch this year, including one for obesity. Mantle cell lymphoma is a rare type of blood cancer that starts in white blood cells in the lymph nodes and aggressively spreads to other parts of the body. The trial assessed the efficacy of 200 mg dose of the drug until disease progression or unacceptable toxicity.
0 next >>
Total: 4